RMD

1 Day 1D

5 Days 5D

1 Month 1M

6 Months 6M

YTD YTD

1 Year 1Y

5 Years 5Y

About Resmed Inc.

ResMed pioneers innovative solutions that treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. Its digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, COPD, and other chronic diseases. Its comprehensive out-of-hospital software platforms support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. By enabling better care, the company improves quality of life, reduces the impact of chronic disease, and lowers costs for consumers and healthcare systems in more than 140 countries.
CEO
Michael Farrell
Employees
7770
Headquarters

9001 Spectrum Center Blvd
San Diego, California 92123-1438
Phone: 18587462400
www.resmed.com

News

ResMed Unusual Options Activity
Apr 23, 2024 14:30pm

Benzinga''s options scanner just detected over 10 options trades for ResMed (NYSE: RMD ) summing a total amount of $532,171. At the same time, our algo caught 3 for a total amount of 179,581. Predicted Price Range Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $175.0 to $200.0 for ResMed over the last 3 months. Insights into Volume & Open Interest Looking at the volume and open interest is an insightful way to conduct due diligence on a stock. This data can help you track the liquidity and interest for ResMed''s options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of ResMed''s whale activity within a strike price range from $175.0 … Full story available on Benzinga.com


Source:Benzinga
How The Weight-Loss Bonanza Prompted A ResMed Sell-Off — But Could Soon Drive Shares Higher
Apr 18, 2024 14:33pm

ResMed stock jumped Thursday after an analyst suggested the growing popularity of weight-loss drugs could drive use of its medical devices.


Source:Investor''s Business Daily
Why Eli Lilly Stock Beat the Market Today While ResMed and AdaptHealth Sank
Apr 17, 2024 22:51pm

The company published some very good news from the lab, although it wasn''t so encouraging for smaller rivals.


Source:The Motley Fool
ResMed Unusual Options Activity For April 17
Apr 17, 2024 13:46pm

Whales with a lot of money to spend have taken a noticeably bullish stance on ResMed . Looking at options history for ResMed (NYSE: RMD ) we detected 10 trades. If we consider the specifics of each trade, it is accurate to state that 60% of the investors opened trades with bullish expectations and 40% with bearish. From the overall spotted trades, 6 are puts, for a total amount of $316,230 and 4, calls, for a total amount of $287,536. Predicted Price Range Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $170.0 to $195.0 for ResMed over the last 3 months. Insights into Volume & Open Interest Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for ResMed''s options for a given strike price. Below, we can observe the evolution of the … Full story available on Benzinga.com


Source:Benzinga
Eli Lilly Pops After Weight-Loss Drug Succeeds In Sleep Apnea Test; ResMed Dives
Apr 17, 2024 12:57pm

Eli Lilly stock popped Wednesday — and pushed ResMed stock lower — after its weight-loss drug reduced sleep apnea symptoms.


Source:Investor''s Business Daily
ASX stocks at risk from Ozempic – and ResMed isn’t one of them
Apr 17, 2024 00:13am

Morgan Stanley brokers say the explosion of interest in the weight loss drugs will be far bigger than first thought. And these major companies could get hit.


Source:The Australian Financial Review
U.S. Digital Therapeutics Market See Incredible Growth 2024-2031 | 2Morrow Inc., ResMed, Pear Therapeutics.
Apr 15, 2024 07:07am

BURLINGAME, CALIFORNIA, UNITED STATE, April 15, 2024 /⁨EINPresswire.com⁩/ -- Coherent Market Insights introduces new research on the U.S. Digital Therapeutics Market covering the micro level of analysis by competitors and key business segments ( …


Source:EIN News Marijuana
Needham sees BSX, CNMD, RMD beating Street, despite medtech slow down
Apr 14, 2024 21:56pm

Needham estimates Q1 medtech sales grew less than expected, but that Boston Scientific, CONMED, ResMed and Surmodics should still be able to beat the Street. Read more here.


Source:Seeking Alpha
ResMed to Report Third Quarter Fiscal 2024 Earnings on April 25, 2024
Apr 04, 2024 20:05pm

SAN DIEGO, April 04, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the third quarter of fiscal year 2024 on Thursday, April 25, 2024, after the New York Stock Exchange closes. Following the release, ResMed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast.


Source:GlobeNewswire
Resmed Inc Reports Increased CDIs in March
Apr 04, 2024 09:49am

Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (AU:RMD) has released an update. Resmed Inc has reported a net increase of 4…


Source:TipRanks